34βE12 expression along the whole spectrum of neuroendocrine proliferations of the lung, from neuroendocrine cell hyperplasia to small cell carcinoma

Stürm, Nathalie; Rossi, Giulio; Lantuéjoul, Sylvie; Mh, Laverrière; Papotti, Mauro; Py, Brichon; Brambilla, Christian; Brambilla, Élisabeth

doi:10.1046/j.1365-2559.2003.01541.x

Cited by 65 publications

(35 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Morphologic small cell carcinomas showing the typical immunohistochemical profile (TTF-1 þ /p16 þ /p63À), except for reactivity of some cells with high molecular weight keratin, should be carefully scrutinized for populations of large neoplastic cells. Our results support the recent report by Sturm et al, 10 who noted the utility of this stain for highlighting small populations of neoplastic large cells in predominant small cell carcinomas that were not obviously combined neoplasms histologically.…”

Section: Discussionsupporting

confidence: 92%

“…[2][3][4][5][6] Recent studies suggest the potential utility of several newer antibodies including thyroid transcription factor-1 (TTF-1), p63, p16(INK4A) (p16), and high molecular weight keratin, to help differentiate between small cell carcinomas and non-small cell carcinomas. [7][8][9][10] In this study, we evaluated the utility of a panel of these antibodies for distinguishing between small cell carcinoma and poorly differentiated squamous cell carcinoma.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach

et al. 2005

View full text Add to dashboard Cite

Accurate morphologic distinction between small cell carcinoma and poorly differentiated squamous cell carcinoma has critical therapeutic significance, but can be limited by crush artifact, tumor necrosis, limited tumor representation, and overlapping morphologic features. We evaluated a panel of antibodies for their efficacy in distinguishing between these neoplasms. Formalin-fixed paraffin-embedded tissue sections of small cell carcinomas and poorly differentiated squamous cell carcinomas underwent immunohistochemical staining with antibodies to thyroid transcription factor-1, p63, high molecular weight keratin, and p16(INK4A). Of 28 small cell carcinomas, 26 (93%) small cell carcinomas showed diffuse moderate or strong staining for thyroid transcription factor-1 with no staining for high molecular weight keratin and p63. In contrast, 27/28 (96%) poorly differentiated squamous cell carcinomas manifested opposite immunoreactivities, with diffuse moderate or strong staining for high molecular weight keratin and p63, and no or minimal staining for thyroid transcription factor-1. In two additional cases originally interpreted as small cell carcinoma, high molecular weight keratin highlighted small numbers of neoplastic large cells, leading to reclassification as combined small cell and nonsmall cell carcinomas. p16(INK4A) expression varied widely in poorly differentiated squamous cell carcinomas, but was consistently moderate or strong and diffuse in small cell carcinomas, and proved helpful in the two thyroid transcription factor-1-negative small cell carcinomas. This study demonstrates that a panel consisting of antibodies to thyroid transcription factor-1, p63, high molecular weight keratin, and p16(INK4A) is highly effective for distinguishing between small cell carcinoma and poorly differentiated squamous cell carcinoma. This panel also facilitates diagnosis of combined small cell and non-small cell carcinomas.

show abstract

Section: Discussionsupporting

confidence: 92%

mentioning

confidence: 99%

Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Recently, a few of these markers, including the newlyidentified AMCAR/P504S, HMW keratin and GSTp1, have been used or is under development to distinguish benign from malignant prostate cancers. [32][33][34][35][36][37][38][39][40][41][42][43][44] G-protein coupled receptors (GPCRs) receive many of the neural, hormonal, chemical and paracrine inputs to activate different types of cells, regulating intracellular second messengers and a variety of cellular functions, including cell growth and proliferation. GPCRs and their signal transduction pathways represent important specific targets for a variety of human diseases, ranging from the control of blood pressure, hormonal disorders and neurological diseases, to tumorigenesis.…”

mentioning

confidence: 99%

PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer

Weng

Wang

et al. 2005

Int. J. Cancer

View full text Add to dashboard Cite

The G-protein coupled receptors (GPCRs) recognize a large variety of extracellular molecules (such as hormones, neurotransmitters, growth and developmental factors) and several sensory messages (such as light, odors and pain). GPCRs and their signal transduction pathway represent important specific targets for a variety of human diseases. To investigate the potential roles of GPCRs in human normal prostate and prostate cancers, we identified and characterized a novel human G-protein coupled receptor, PSGR2, which is highly overexpressed in human prostate cancers. Although PSGR2 shares sequence homology with human olfactory G-protein coupled receptors, the expression of PSGR2 is highly restricted to human prostate tissue, and no expression was detected in 22 normal and 10 tumor tissues examined using Northern blot and PCR analysis. Furthermore, we investigated the expression levels of PSGR2 in 133 human prostate samples with real-time quantitative reverse transcription-PCR and in situ hybridization method. We demonstrated that PSGR2 expression increased significantly in human high grade prostate intraepithelial neoplasia (PIN) and prostate cancers (approximately 10-fold) as compared to normal and BPH (benign prostatic hyperplasia) tissues (p < 0.001), suggesting PSGR2 may play an important role in human prostate cancer development and progression. Together, our results suggest that PSGR2 is a novel prostate specific G-protein coupled receptor and may be useful as a tissue marker and molecular target for the early detection and treatment of human prostate cancers. ' 2005 Wiley-Liss, Inc.

show abstract

“…Both display an epithelial immunoprofile, with wide spectrum cytokeratin expression, which may occasionally have a paranuclear dot-like distribution, especially in the case of SCC. Conversely, high-molecularweight cytokeratins (types 1, 5, 10, 14 of the Moll's catalog) are typically absent in the vast majority of NE differentiated carcinomas irrespective of the location [21,22]. Among NE markers, chromogranin A (more often with a focal paranuclear dot-like pattern unmasked by heat-induced antigen retrieval procedures) and synaptophysin are the most reliable molecules supporting the morphological evaluation, while neuron-specific enolase (NSE) and CD56 are sensitive but much less specific.…”

Section: Issue 1 221 Problem: How To Label These Tumors?mentioning

confidence: 99%

Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues

et al. 2014

View full text Add to dashboard Cite

Summary Extrapulmonary neuroendocrine carcinoma (EPNEC) is a heterogeneous and rare group of high-grade neoplasms occurring in different organs. They usually share a poor prognosis, but diagnostic and therapeutic options still include several controversial issues, due to the rarity of this condition and to differences in architecture and cell size, being some cases pure small cell carcinomas, other pure large cell neuroendocrine carcinomas and some others combined/mixed neuroendocrine carcinomas with a conventional non-neuroendocrine carcinoma. In addition, the therapeutic strategy varies in different organs (surgery and/or chemotherapy and/or radiation therapy and/or targeted treatments), and clinicians and pathologists are asked to interact to reach an accurate classification of every single case, as well as the most appropriate selection of the treatment options, even considering different time points of each EPNEC natural history. This overview highlights controversial pathological and clinical issues and summarizes possible solutions to most of such EPNEC-related problems.

show abstract

34βE12 expression along the whole spectrum of neuroendocrine proliferations of the lung, from neuroendocrine cell hyperplasia to small cell carcinoma

Abstract: We conclude that 34betaE12 expression excludes the neuroendocrine nature of tumour cells and uncovers the real frequency of combined forms in high-grade neuroendocrine tumours.

Cited by 65 publications

References 40 publications

Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach

Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach

PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer

Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues

Contact Info

Product

Resources

About